Viatris announces remaining divestitures to slim down focus

3 October 2023

USA-based drugmaker Viatris (Nasdaq: VTRS) has announced a series of divestitures as part of a strategy to narrow the company’s focus.

Viatris has received an offer to sell substantially all of its over-the-counter (OTC) unit, and has entered into definitive agreements to divest its women's healthcare business, its active pharmaceutical ingredients (API) business in India and commercialization rights in certain non-core markets that were acquired as part of the Upjohn legacy company of Pfizer (NYSE: PFE) transaction.

"An important milestone in the execution of our overall strategic plan"Chief executive Scott Smith said: “I am very excited about today's announcement as it marks an important milestone in the execution of our overall strategic plan.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK